Guggenheim raised the firm’s price target on Cabaletta Bio (CABA) to $16 from $15 and keeps a Buy rating on the shares after the company reported Q4 results and said that its FDA-aligned registrational myositis trial is on track to support a potential BLA submission in 2027. The firm cites “a growing body of robust efficacy data, and consistent clinical execution” for its increased target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Midday Fly By: Musk to start Terafab project, Elliott takes stake in Synopsys
- Cabaletta Bio Updates Rese-cel Programs and Financial Outlook
- Cabaletta Bio reports Q4 EPS (40c), consensus (47c)
- Cabaletta Bio, Inc. (CABA) Q4 Earnings Cheat Sheet
- Cabaletta Bio participates in a conference call with William Blair